Journal
CLINICAL CANCER RESEARCH
Volume 13, Issue 1, Pages 170-181Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-06-1508
Keywords
-
Categories
Funding
- NCI NIH HHS [CA102774, CA102613, P01 CA 47179] Funding Source: Medline
- NIDDK NIH HHS [HL/DK55748] Funding Source: Medline
Ask authors/readers for more resources
Purpose: Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the intestinal tract. Nearly all tumors express KIT protein, and most have an activating mutation in either KIT or PDGFRA. Therapy with selective tyrosine kinase inhibitors achieves a partial response or stable disease in similar to 80% of patients with advanced GIST However, after an initial clinical response, some patients develop imatinib resistance. Our goal was to investigate the spectrum of pathologic response and molecular alterations in a group of GIST patients, clinically defined as having imatinib-stable/imatinib-responsive lesions, who underwent surgical resection. Experimental Design: Forty-three tumor nodules from 28 patients were available for pathologic and molecular analysis, which included genotyping for primary and secondary KIT/PDGFRA-mutations, cell cycle alterations, and biochemical activation status of KIT and downstream targets. The transcriptional changes of a subset of these tumors were compared with a group of imatinib-naive GISTS on a U133A Affymetrix expression platform. Results: The histologic response did not correlate with imatinib therapy duration or with proliferative activity. Second-site KIT mutation was identified in only one tumor nodule. Activation of KIT and downstream targets was consistent in all tumors analyzed. Ultrastructurally, a subset of tumors showed a smooth muscle phenotype, which correlated with overexpression of genes involved in muscle differentiation and function. Conclusions:The histologic response to imatinib is heterogeneous and does not correlate well with clinical response. Second-site KIT mutations are rare in imatinib-responsive GISTS compared with imatinib-resistant tumors. The gene signature of imatinib-response in GISTS showed alterations of cell cycle control as well as up-regulation of genes involved in muscle differentiation and function.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available